Galmed Pharmaceuticals (EOCN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.85, -6.55% vs the prior close of $3.05.
- Volume 10.97K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
EOCN slides 6.6% to $2.85, a 52-week low. Closed at $2.85, -6.55% vs the prior close of $3.05. Day range $2.33β$3.09, opened at $2.91.
EOCN daily analysis β what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 β EOCN slides 6.6% to $2.85, a 52-week low
- Closed at $2.85, -6.55% vs the prior close of $3.05. Day range $2.33β$3.09, opened at $2.91.
- Volume was 10.97K shares, 0.4x its 50-day average of 29.30K β lighter than usual.
- Price is -26.0% vs its 50-day average ($3.85) and -40.2% vs its 200-day average ($4.76).
- 52-week range $2.33β$12.32; today's close sits at 5% of that range, 76.9% below the 52-week high.
Oct 15, 2026 β EOCN rises 1.3% to $3.05
- Closed at $3.05, +1.33% vs the prior close of $3.01. Day range $2.92β$3.16, opened at $2.92.
- Volume was 2.00K shares, 0.1x its 50-day average of 29.32K β lighter than usual.
- Price is -21.7% vs its 50-day average ($3.89) and -36.2% vs its 200-day average ($4.78).
- 52-week range $2.67β$12.32; today's close sits at 4% of that range, 75.2% below the 52-week high.
Oct 14, 2026 β EOCN slides 4.9% to $3.01, a 52-week low, 4 down days in a row
- Closed at $3.01, -4.90% vs the prior close of $3.16. Day range $2.67β$3.13, opened at $3.13.
- Volume was 9.80K shares, 0.3x its 50-day average of 29.24K β lighter than usual.
- Price is -23.3% vs its 50-day average ($3.92) and -37.2% vs its 200-day average ($4.80).
- 52-week range $2.67β$12.32; today's close sits at 4% of that range, 75.6% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 β EOCN dips 1.7% to $3.16, a 52-week low, 3 down days in a row
- Closed at $3.16, -1.71% vs the prior close of $3.22. Day range $3.10β$3.37, opened at $3.23.
- Volume was 9.10K shares, 0.3x its 50-day average of 29.24K β lighter than usual.
- Price is -20.0% vs its 50-day average ($3.96) and -34.3% vs its 200-day average ($4.82).
- 52-week range $3.10β$12.32; today's close sits at 1% of that range, 74.3% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 β EOCN slides 9.0% to $3.22, a 52-week low
- Closed at $3.22, -9.04% vs the prior close of $3.54. Day range $3.22β$3.41, opened at $3.41.
- Volume was 9.50K shares, 0.3x its 50-day average of 29.40K β lighter than usual.
- Price is -19.2% vs its 50-day average ($3.99) and -33.4% vs its 200-day average ($4.83).
- 52-week range $3.12β$12.80; today's close sits at 1% of that range, 74.8% below the 52-week high.
Oct 9, 2026 β EOCN dips 2.2% to $3.54
- Closed at $3.54, -2.21% vs the prior close of $3.62. Day range $3.46β$3.60, opened at $3.46.
- Volume was 4.70K shares, 0.2x its 50-day average of 29.58K β lighter than usual.
- Price is -12.0% vs its 50-day average ($4.02) and -27.1% vs its 200-day average ($4.85).
- 52-week range $3.12β$12.88; today's close sits at 4% of that range, 72.5% below the 52-week high.
Oct 8, 2026 β EOCN jumps 4.7% to $3.62
- Closed at $3.62, +4.68% vs the prior close of $3.46. Day range $3.42β$3.63, opened at $3.61.
- Volume was 14.80K shares, 0.5x its 50-day average of 29.50K β lighter than usual.
- Price is -10.5% vs its 50-day average ($4.05) and -25.7% vs its 200-day average ($4.87).
- 52-week range $3.12β$12.88; today's close sits at 5% of that range, 71.9% below the 52-week high.
Oct 7, 2026 β EOCN rises 2.9% to $3.46
- Closed at $3.46, +2.92% vs the prior close of $3.36. Day range $3.35β$3.63, opened at $3.49.
- Volume was 8.50K shares, 0.2x its 50-day average of 37.43K β lighter than usual.
- Price is -14.9% vs its 50-day average ($4.06) and -29.3% vs its 200-day average ($4.89).
- 52-week range $3.12β$13.20; today's close sits at 3% of that range, 73.8% below the 52-week high.
Oct 6, 2026 β EOCN dips 2.6% to $3.36, a 52-week low
- Closed at $3.36, -2.61% vs the prior close of $3.45. Day range $3.28β$3.56, opened at $3.45.
- Volume was 10.20K shares, 0.3x its 50-day average of 37.37K β lighter than usual.
- Price is -17.7% vs its 50-day average ($4.08) and -31.5% vs its 200-day average ($4.91).
- 52-week range $3.12β$13.20; today's close sits at 2% of that range, 74.5% below the 52-week high.
Oct 5, 2026 β EOCN slides 4.4% to $3.45
- Closed at $3.45, -4.43% vs the prior close of $3.61. Day range $3.45β$3.62, opened at $3.55.
- Volume was 7.70K shares, 0.2x its 50-day average of 37.27K β lighter than usual.
- Price is -15.8% vs its 50-day average ($4.10) and -30.0% vs its 200-day average ($4.93).
- 52-week range $3.12β$13.20; today's close sits at 3% of that range, 73.9% below the 52-week high.
Oct 2, 2026 β EOCN jumps 6.0% to $3.61
- Closed at $3.61, +6.02% vs the prior close of $3.40. Day range $3.26β$3.62, opened at $3.33.
- Volume was 4.90K shares, 0.1x its 50-day average of 37.70K β lighter than usual.
- Price is -12.2% vs its 50-day average ($4.11) and -27.0% vs its 200-day average ($4.95).
- 52-week range $3.12β$13.20; today's close sits at 5% of that range, 72.7% below the 52-week high.
EOCN latest news & SEC filings
Every SEC filing by or about EOCN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 9, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Sep 8, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Sep 3, 2026 Β· Form EFFECT β EFFECT filing
EFFECT filing
Sep 3, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Sep 2, 2026 Β· Form POS AM β POS AM filing
POS AM filing
Sep 2, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Sep 2, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Aug 19, 2026 Β· Form 6-K/A β 6-K/A filing
6-K/A filing
Aug 19, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Aug 17, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Aug 14, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Jul 31, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Jul 29, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Jul 28, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Jul 22, 2026 Β· Form 6-K β Report from a foreign company (6-K)
Report from a foreign company (6-K) β news it published at home
Things to know before you trade EOCN
- How much it moves: over the last 20 sessions the average daily move was 3.03% (largest 9.0%). That is a volatile stock.
- Liquidity: about 7.38K shares (β$21.03K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.85 vs a range of $2.33β$12.32 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:8 on Aug 19, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Sep 9, 2026; 6-K Sep 8, 2026; 6-K Sep 3, 2026.
- Listing: Nasdaq Β· industry: Pharmaceutical Preparations.
EOCN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.91 | 3.09 | 2.33 | 2.85 | 10.97K |
| Oct 15, 2026 | 2.92 | 3.16 | 2.92 | 3.05 | 2.00K |
| Oct 14, 2026 | 3.13 | 3.13 | 2.67 | 3.01 | 9.80K |
| Oct 13, 2026 | 3.23 | 3.37 | 3.10 | 3.16 | 9.10K |
| Oct 12, 2026 | 3.41 | 3.41 | 3.22 | 3.22 | 9.50K |
| Oct 9, 2026 | 3.46 | 3.60 | 3.46 | 3.54 | 4.70K |
| Oct 8, 2026 | 3.61 | 3.63 | 3.42 | 3.62 | 14.80K |
| Oct 7, 2026 | 3.49 | 3.63 | 3.35 | 3.46 | 8.50K |
| Oct 6, 2026 | 3.45 | 3.56 | 3.28 | 3.36 | 10.20K |
| Oct 5, 2026 | 3.55 | 3.62 | 3.45 | 3.45 | 7.70K |
| Oct 2, 2026 | 3.33 | 3.62 | 3.26 | 3.61 | 4.90K |
| Oct 1, 2026 | 3.14 | 3.62 | 3.12 | 3.40 | 12.60K |
| Sep 30, 2026 | 3.45 | 3.49 | 3.39 | 3.49 | 2.60K |
| Sep 29, 2026 | 3.60 | 3.63 | 3.50 | 3.55 | 5.60K |
| Sep 28, 2026 | 3.46 | 3.63 | 3.46 | 3.63 | 3.90K |
| Sep 25, 2026 | 3.62 | 3.80 | 3.56 | 3.63 | 3.40K |
| Sep 24, 2026 | 3.75 | 3.75 | 3.62 | 3.62 | 3.00K |
| Sep 23, 2026 | 3.47 | 3.65 | 3.46 | 3.62 | 5.40K |
| Sep 22, 2026 | 3.67 | 3.80 | 3.45 | 3.62 | 15.80K |
| Sep 21, 2026 | 3.33 | 3.66 | 3.33 | 3.50 | 3.10K |
About Galmed Pharmaceuticals
Galmed Pharmaceuticals (EOCN) is listed on the Nasdaq and classified by the SEC under βPharmaceutical Preparationsβ. Its business address is in RAMAT GAN, Israel. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 1595353.
EOCN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Allen Baharaff | Chief Executive Officer | Mar 18, 2026 |
| Carol L Brosgart | Director | Mar 18, 2026 |
| Shmuel Nir | Director | Mar 18, 2026 |
| Amir Poshinski | Director | Mar 18, 2026 |
| David Sidransky | Director | Mar 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Allen Baharaff | Chief Executive Officer | Mar 18, 2026 |
| Doron Leib Cohen | Chief Financial Officer | Mar 18, 2026 |
| Guy Nehemya | Chief Operating Officer | Mar 18, 2026 |
| Brueck Liat Nissimov | Chief Scientific Officer | Mar 18, 2026 |
| Yohai Stenzler | Chief Accounting Officer | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
EOCN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $β, total liabilities $β, cash $β.
EOCN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks Β· Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on EOCN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.